ArticleJournal of glaucoma2025
Comparison Between Phacoemulsification-iStent Inject W and Phacoemulsification-Micropulse Transscleral Laser Therapy in Asian Eyes With Mild-Moderate Open Angle Glaucoma.
Article in Journal of glaucoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Precision Glaucoma Surgery: A Mechanism-Based Review of MIGS and Contemporary Surgical Pathways.Journal of clinical medicine · 2026Review
- Clinical outcomes of combined cataract surgery with iStent injectGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PRÉCIS: In this retrospective cohort study, the 1-year cumulative probability of failure was comparable, achieving 52.20% in the phacoemulsification-iStent inject W (phaco/iStent) group and 47.80% in the phacoemulsification-micropulse transscleral laser therapy (phaco/MPTLT) group ( P =0.994). PURPOSE: To compare the 1-year efficacy and safety of phacoemulsification combined with iStent Inject W (phaco/iStent) and phacoemulsification combined with micropulse transscleral laser therapy (phaco/MPTLT).
methodsA retrospective cohort study that included patients with mild-moderate open angle glaucoma (OAG) and cataract who underwent either phaco/iStent or phaco/MPTLT in a tertiary hospital in Singapore between August 1, 2016 and December 31, 2022. The primary outcome measures were cumulative probabilities of failure between the 2 groups, with failure defined as disease progression by ocular coherence tomography (OCT-RNFL) or visual field test (VFT), repeat glaucoma surgery, and inability to maintain intraocular pressure (IOP) lower than preoperative baseline or the use of glaucoma medications for 2 consecutive visits after 1 month postoperatively. In addition, postoperative mean IOP, average number of IOP lowering medications, visual acuity, and complications were analyzed.
resultsForty-six patients were included. Twenty-three eyes underwent phaco/iStent and 23 had phaco/MPTLT. The 2 groups had comparable cumulative probabilities of failure (52.20% phaco/iStent, 47.80% phaco/MPTLT; P =0.994) and mean IOP (15.57±2.95 mm Hg phaco /iStent, 14.39±2.25 mm Hg phaco/MPTLT; P =0.136) after 1 year. The change in IOP before surgery to 12 months is -1.04±3.07 mm Hg in the phaco/iStent group ( P =0.593) and -2.43±4.12 mm Hg in the phaco/MPTLT group ( P =0.022). Both achieved significant medication reduction burdens ( P <0.05). Intraoperative and postoperative complication rates were similar.
conclusionBoth groups showed comparable surgical efficacy and safety after 1 year. The phaco/MPTLT group demonstrated sustained IOP reduction 1 year postoperatively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.